Editact Therapeutics has been selected as a top 5 finalist in the EQT Impact Challenge, 2025. The contest aims to find the leading pre-seed or early stage company to receive a grant and technical assistance from EQT, a global investment organisation with a strong track record in scaling innovative ventures. Over 200 entrants initially competed for the chance to impress with their breakthrough concepts, business plans, financial models and ambitions to scale for long-term growth. From the initial pool, 10 including Editact were shortlisted for jury deliberation, where the groups had the opportunity to pitch their business ideas to a panel of experienced judges.